Despite the benefits promoted by induction regimens based on HDAC in MCL, up-front consolidation with ASCT promotes increased overall survival and is being incorporated into the primary therapeutic strategy of young and fit patients with MCL by many international research groups [21,22,23,24,25]. The gene discussed is HDAC9; the disease is mantle cell lymphoma.